Skip to main content

Press releases | December 4, 2025

Fried Frank advised Merck & Co., Inc., as issuer, in its $8 billion, eight-tranche registered public offering of US dollar-denominated senior notes. Merck & Co., Inc. intends to use the net proceeds of the offering for general corporate purposes including to repay outstanding indebtedness, as well as potentially to fund a portion of the cash consideration and related fees and expenses payable in connection with its acquisition of Cidara Therapeutics, Inc. Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. 

This transaction is a continuation of Fried Frank’s work advising leading companies on high-value offerings.

The Fried Frank team was led by corporate partners Daniel J. Bursky and Andrew B. Barkan and included tax partner Joseph E. Fox, corporate special counsel Charles Stern and corporate associate Jack Madigan.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.